secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001437749-25-016262
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar Q1 net loss $2.6M, cash $54.6M; ALXN1840 NDA planned early 2026
-----------------------------------------------------------------------

- Cash $54.6M as of March 31, 2025; expected runway through Dec 2026 for NDA and trials.
- Net loss $2.6M ($0.38/sh) vs $1.6M ($0.51/sh) YoY; R&D expense rose 70% to $1.643M.
- ALXN1840 data presented at EASL; NDA submission to FDA planned early 2026.
- MNPR-101-Zr and MNPR-101-Lu Phase 1 trials active in Australia; preclinical Ac-225 program advancing.
- G&A expense doubled to $1.578M, driven by stock option grants and higher personnel costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774925016262/0001437749-25-016262-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774925016262/mnpr20250508_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-016262

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer